Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ: HRMY · Real-Time Price · USD
42.02
-0.72 (-1.68%)
At close: Sep 18, 2026, 4:00 PM EDT
42.15
+0.13 (0.31%)
Pre-market: Sep 21, 2026, 5:00 AM EDT
HRMY Revenue
Harmony Biosciences Holdings had revenue of $261.28M in the quarter ending June 30, 2026, with 30.32% growth. This brings the company's revenue in the last twelve months to $959.90M, up 24.25% year-over-year. In the year 2025, Harmony Biosciences Holdings had annual revenue of $868.45M with 21.51% growth.
Revenue (ttm)
$959.90M
Revenue Growth
+24.25%
P/S Ratio
2.55
Revenue / Employee
$3,276,102
Employees
293
Market Cap
2.45B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 868.45M | 153.72M | 21.51% |
| Dec 31, 2024 | 714.73M | 132.71M | 22.80% |
| Dec 31, 2023 | 582.02M | 144.17M | 32.93% |
| Dec 31, 2022 | 437.86M | 132.42M | 43.35% |
| Dec 31, 2021 | 305.44M | 145.70M | 91.21% |
| Dec 31, 2020 | 159.74M | 153.75M | 2,564.59% |
| Dec 31, 2019 | 6.00M | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Beam Therapeutics | 156.04M |
| Viridian Therapeutics | 71.13M |
| Nektar Therapeutics | 54.59M |
| Nurix Therapeutics | 36.77M |
| NewAmsterdam Pharma Company | 7.12M |
HRMY News
- 10 days ago - Harmony Biosciences Holdings Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 17 days ago - Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress - GlobeNewsWire
- 24 days ago - Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference - GlobeNewsWire
- 25 days ago - Harmony Biosciences initiated with an Outperform at Wolfe Research - TheFly
- 5 weeks ago - Harmony Biosciences Holdings Transcript: Piper Sandler Virtual CNS Symposium - Transcripts
- 6 weeks ago - Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium - GlobeNewsWire
- 6 weeks ago - Harmony Biosciences price target raised to $34 from $29 at Truist - TheFly
- 6 weeks ago - Harmony Biosciences price target raised to $39 from $36 at Deutsche Bank - TheFly